OBJECTIVE: To evaluate the prognostic value of p53 in colorectal cancer. DESIGN: A retrospective study to investigate the correlation between p53 in tumour tissue and the course of patients' disease. PATIENTS: One hundred and two patients who underwent radical surgery for colorectal cancer and were followed up for a minimum of 5 years, or until death, were included in this study. METHODS: The p53 expression in tumour tissue was studied by immunohistochemistry using CM1 polyclonal rabbit antibody and formalin-fixed, paraffin-embedded material. RESULTS: p53 accumulation was detected in 46% (47/102) of the tumours. There was no significant difference in long-term survival between the patients with p53 positive and negative tumours (P=0.86). Five-year survival rates were 55% for p53 positive tumours compared with 56% for patients with p53 negative tumours. However, patients with p53 overexpressing tumours showed a higher local recurrence rate than those having carcinomas with undetectable levels of p53, 23% versus 9% respectively; the 2-year actuarial rates of 26% and 9% were statistically different (P=0.015). CONCLUSION: The results suggest that in colorectal carcinoma accumulation of p53 is not associated with a difference in long-term prognosis. However, this phenomenon might be useful in the identification of patients with a high risk of local recurrence.
OBJECTIVE: To evaluate the prognostic value of p53 in colorectal cancer. DESIGN: A retrospective study to investigate the correlation between p53 in tumour tissue and the course of patients' disease. PATIENTS: One hundred and two patients who underwent radical surgery for colorectal cancer and were followed up for a minimum of 5 years, or until death, were included in this study. METHODS: The p53 expression in tumour tissue was studied by immunohistochemistry using CM1 polyclonal rabbit antibody and formalin-fixed, paraffin-embedded material. RESULTS:p53 accumulation was detected in 46% (47/102) of the tumours. There was no significant difference in long-term survival between the patients with p53 positive and negative tumours (P=0.86). Five-year survival rates were 55% for p53 positive tumours compared with 56% for patients with p53 negative tumours. However, patients with p53 overexpressing tumours showed a higher local recurrence rate than those having carcinomas with undetectable levels of p53, 23% versus 9% respectively; the 2-year actuarial rates of 26% and 9% were statistically different (P=0.015). CONCLUSION: The results suggest that in colorectal carcinoma accumulation of p53 is not associated with a difference in long-term prognosis. However, this phenomenon might be useful in the identification of patients with a high risk of local recurrence.
Authors: B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor Journal: Int J Colorectal Dis Date: 2003-06-21 Impact factor: 2.571
Authors: Helen L Spencer; Angela M Eastham; Catherine L R Merry; Thomas D Southgate; Flor Perez-Campo; Francesca Soncin; Sarah Ritson; Rolf Kemler; Peter L Stern; Christopher M Ward Journal: Mol Biol Cell Date: 2007-05-16 Impact factor: 4.138
Authors: Young Eun Joo; Young Hae Sohn; Wan Sik Lee; Chang Hwan Park; Sung Kyu Choi; Jong Sun Rew; Chang Soo Park; Sei Jong Kim Journal: Korean J Intern Med Date: 2002-09 Impact factor: 2.884